Precision Medicine in Action: Multi-Tracer PET/CT Uncovers Tumor Heterogeneity and a Synchronous Malignancy

AbstrAct

Precision oncology leverages molecular profiling to tailor cancer treatment, with nuclear medicine playing an increasingly central role, particularly in elderly patients, where noninvasive approaches are preferable. We present a case of a 76-year-old male with metastatic prostate carcinoma (Gleason score: 5 + 5 = 10) exhibiting neuroendocrine differentiation. Imaging with multiple positron emission tomography (PET) tracers—⁶⁸Ga-PSMA, ¹⁸F-FDG, ⁶⁸Ga-DOTATATE, and ⁶⁸Ga-FAPI—revealed significant tumor heterogeneity. Tumor heterogeneity is multifactorial, influenced not only by genetic changes but also by epigenetic, microenvironmental, and therapeutic pressures. While ⁶⁸Ga-PSMA PET/computed tomography (CT) showed variable expression in osteosclerotic lesions, ¹⁸F-FDG PET/CT detected metabolic activity, and ⁶⁸Ga-DOTATATE PET/CT confirmed low somatostatin receptor expression. Despite ¹⁷⁷Lu-PSMA radioligand therapy, the disease progressed with rising prostate-specific antigen levels. Subsequent gastrointestinal symptoms led to the diagnosis of sigmoid colon adenocarcinoma, confirmed by ⁶⁸Ga-FAPI PET/CT. This case exemplifies the critical role of nuclear imaging in characterizing tumor biology, guiding therapeutic strategies, and reducing reliance on invasive procedures. The integration of multi-tracer PET imaging enabled a nuanced understanding of tumor evolution, reinforcing nuclear medicine's importance in precision oncology and the management of complex, heterogeneous malignancies.

Keywords

multi-tracer PET/CT - tumor heterogeneity - precision oncology - neuroendocrine differentiation - nuclear medicine

Publication History

Article published online:
23 November 2025

• References

• 1 Schwartzberg L, Kim ES, Liu D, Schrag D. Precision oncology: who, how, what, when, and when not?. Am Soc Clin Oncol Educ Book 2017; 37 (37) 160-169
• 2 Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013; 108 (03) 479-485
• 3 Bailly C, Bodet-Milin C, Bourgeois M. et al. Exploring tumor heterogeneity using PET imaging: the big picture. Cancers (Basel) 2019; 11 (09) 1282
• 4 Liu Y, Niu S, Luan X. et al. Can ¹⁸F-PSMA-7Q PET/CT replace prostate biopsy for the diagnosis of prostate cancer?-a single-center retrospective study. Transl Androl Urol 2023; 12 (01) 83-89
• 5 Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol 2014; 2 (04) 273-285
• 6 Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol 2015; 5: 90
• 7 Bakht MK, Derecichei I, Li Y. et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer 2018; 26 (02) 131-146
• 8 Parida GK, Tripathy S, Datta Gupta S. et al. Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT over 68Ga-PSMA PET/CT. Clin Nucl Med 2018; 43 (04) 248-249
• 9 Kratochwil C, Flechsig P, Lindner T. et al. ⁶⁸Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 2019; 60 (06) 801-805
• 10 Chen H, Pang Y, Wu J. et al. Comparison of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 2020; 47 (08) 1820-1832